<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135041</url>
  </required_header>
  <id_info>
    <org_study_id>B328</org_study_id>
    <nct_id>NCT03135041</nct_id>
  </id_info>
  <brief_title>The Effect of Prebiotic Fibres on Weight Loss in an Overweight and Obese Population</brief_title>
  <acronym>MNGII</acronym>
  <official_title>Effects of a Combination of Prebiotic Fibres on Weight Loss During an Energy Restricted Diet in an Overweight/Obese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TNO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether a diet supplemented with two prebiotic fibres
      induces greater changes in body weight compared to placebo during 12 weeks of energy
      restriction in an obese/overweight population.

      The hypothesis is that the fiber-containing dietary supplement will:

      1) Induce greater changes in body weight compared to the placebo group 2) change the gut
      microbiota composition 3) improve glucose homeostasis 4) decrease serum concentration of
      triglycerides, total and LDL cholesterol

      The hypothesis is that the effect of the intervention on weight loss will be partly mediated
      by the diet-induced changes in the gut microbiota composition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prebiotics are nutrients that specifically utilized by the gut microbiota. Beneficial health
      effects of prebiotics are generally attributed to 1) stimulation of beneficial bacteria and
      SCFA production, and consequently; improved barrier function, regulation of enteroendocrine
      peptide secretion and resistance to inflammatory stimuli; 2) modulation of lipid metabolism,
      possibly by suppression of lipogenic enzymes and thus decreased synthesis of lipoproteins and
      triglycerides; and 3) increased mineral absorption.

      Inulin is recognized as a common prebiotic. Fibersol-2 is a resistant starch that has been
      suggested to induce satiety, when given in a dose of 10 g. Intake of inulin has been shown to
      induce changes in the microbial abundance and increase production of SCFA19; whereas
      resistant starch has been shown to improve insulin sensitivity and postprandial glucose
      AUC20. However, the effects of an intervention with a combination of these two fibers on
      obesity and body composition during an energy restricted diet have not been addressed.
      Supplements with other types of fibres in addition to energy restriction have shown
      additional effects in weight reduction.

      In this study, the effects of a combination product of two prebiotic fibres on additional
      weight loss during energy restriction in a placebo-controlled, randomized parallel study with
      a duration of 12 weeks will be tested. Furthermore, the effects of the fibres on the gut
      microbial composition, markers of metabolic syndrome (MetS) and glucose metabolism will be
      tested. The active diet will contain intervention products high in dietary fibre and the
      placebo diet will contain maltodextrin. The fiber-containing dietary supplements will add
      approximately 20 g of prebiotic fibres per day, where approximately 10 g will be inulin and
      approximately 10 g will be resistant maltodextrin. The intervention products and placebo will
      be consumed as milk. The fiber-containing dietary supplement is expected to induce additional
      weight loss, compared to placebo and to affect the gut microbiome and markers of metabolic
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2017</start_date>
  <completion_date type="Actual">May 24, 2018</completion_date>
  <primary_completion_date type="Actual">May 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Differences in changes in body weight between the group that receives fiber-containing dietary supplement and placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Changes in body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota composition and function</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Changes in gut microbiota composition and function (faecal samples) assesed by metagenomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Glucose and insulin homeostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Analyses of lipids in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Changes in concentration of inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCFA concentration</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Changes in faecal concentration of short chain fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidomics and bile acids</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Changes in concentration of lipids and bile acids in blood and faecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Analyses of metabolites in blood, urine and fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Interaction between differences in changes in body weight between the group that receives fiber-containing dietary supplement and placebo group and each of baseline fasting glucose, baseline fasting insulin and baseline microbiome composition (e.g. enterotype).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Measurement of physical activity, as assessed by Actigraph monitors</description>
  </other_outcome>
  <other_outcome>
    <measure>Appetite regulation</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Markers of appetite regulation</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene expression</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Measurements of gene expression in of selected genes</description>
  </other_outcome>
  <other_outcome>
    <measure>Epigenetics</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Measurements of epigenetic markers in biological samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Blood pressure measured by an automated blood pressure monitor</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver markers</measure>
    <time_frame>Measurements will be performed at baseline and after 12 weeks of intervention</time_frame>
    <description>Measurement of markers of liver health</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Fiber-containing dietary supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fiber-containing dietary supplement</intervention_name>
    <description>Effects of fiber-containing dietary supplement on weight loss during energy restriction</description>
    <arm_group_label>Fiber-containing dietary supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Effects of placebo supplement on weight loss during energy restriction</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI: 28-45 kg/m2

          -  Non-smoking

          -  Haemoglobin level â‰¥7 mmol/L

        Exclusion Criteria:

          -  Use of antibiotics three months prior to study and during the study. If a participant
             uses antibiotics prior to randomization, the participant will be invited to be
             re-screened 3 months after the last use of antibiotics, provided that it is realistic
             to complete the study no later than the scheduled LPLV

          -  Weight change &gt;3 kg two months prior to study

          -  Blood donation other than for this study &lt;1 month prior to study and during study.

          -  Participation in clinical trials other than for this &lt;1 month prior to study and
             during study

          -  Intensive physical training/ elite athlete (&gt;10 hours of strenuous physical activity
             per week)

          -  Unstable medication for dyslipidaemia and elevated blood pressure (the participant
             must have had a stable dose in the three months prior to study start), and use of
             systemic glucocorticoids

          -  Medication for T2D

          -  Treatment with metformin

          -  Dietary supplements with pro- and/or prebiotics and/or fibre 6 weeks prior to study

          -  Special dietary regimen (vegetarians, vegans etc.), as evaluated by study staff

          -  Lactose intolerance or allergy to components in the intervention products

          -  Gluten intolerance

          -  Maltodextrin intolerance

          -  Lactation, pregnancy or planning of pregnancy during the study

          -  Gastro intestinal and liver disorders

          -  Chronic inflammation disorders (excluding obesity)

          -  Diagnosed psychiatric disorder including depression requiring treatment

          -  Surgical treatment of obesity and abdominal surgery

          -  Inability, physically or mentally, to comply with the procedures required by the study
             protocol, as evaluated by the study staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Larsen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nutrition, Exercise and Sports</name>
      <address>
        <city>Frederiksberg</city>
        <state>Frederiksberg C</state>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Thomas Meinert Larsen</investigator_full_name>
    <investigator_title>Associate Professor, PhD</investigator_title>
  </responsible_party>
  <keyword>Prebiotics</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Glucose metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shared personal data collected includes basic data and demographics as well as health related data (weight, blood pressure, medical history etc.) and biological samples including maximum 50 mL blood, faecal samples and spot urine collected at baseline and during the study. The blood samples collected will be used for the analyses of markers of glucose metabolism, lipid metabo-lism and inflammation. Urine collection will be used for metabolomics analyses. Faecal samples will be used for metagenomics analyses and analysis of bile acids. Biological samples will be stored in the research biobank for 5 years and destroyed afterwards.
Link between participant number and personal identification will be separated and stored in one protected participant number log.
Personal data will be stored for 5 years, where data will be anonymized by destroying basic data sheet and participant number log.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

